| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H22FN3O3 |
| Molecular Weight | 407.4375 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C=CN=C2C=C1OCC5(N)CC5
InChI
InChIKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Anlotibib is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Phase III development is underway for the treatment of thyroid cancer, gastric cancer, leiomyosarcoma; non-small cell lung cancer; synovial sarcoma; thyroid cancer etc.
Approval Year
Doses
AEs
PubMed
Sample Use Guides
Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Route of Administration:
Oral
AN3CA cells
appeared the most sensitive to AL3818 with an IC50 value of 84
nM. The other cell lines were approximately 28- to
550-fold less sensitive to AL3818. HEC1B had an IC50 value
of 46 uM, and MFE296 cells were sensitive to AL3818,
with an IC50 value of 2.9 uM compared with 3.2, 28.9, 29,
and 40 uM for Ishikawa, MFE280, KLE, and HEC1A, respectively.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
